[Federal Register Volume 68, Number 167 (Thursday, August 28, 2003)]
[Notices]
[Page 51786]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-22008]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.
    Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).
    Times and Dates: 8:30 a.m.-5 p.m.; September 17, 2003. 8:30 a.m.-
3:30 p.m.; September 18, 2003.
    Place: Sheraton Colony Square Hotel, 188 14th Street NE., Atlanta, 
Georgia 30361.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the standards 
under which clinical laboratories are regulated; the impact on medical 
and laboratory practice of proposed revisions to the standards; and the 
modification of the standards to accommodate technological advances.
    Matters To Be Discussed: The agenda will include updates from CDC, 
the Centers for Medicare & Medicaid Services, and the Food and Drug 
Administration; a report on the results of the General Services 
Administration's Office of Government-wide Policy Federal Advisory 
Committee Stakeholder Engagement Survey; presentations and discussion 
on the CLIA waiver criteria and process, previous CLIAC recommendations 
related to such, and AdvaMed's CLIAC waiver criteria proposal; a report 
on the Coordinating Council for Clinical Laboratory Workforce's June 
2003 meeting; a report on the April 2003 Quality Institute; a summary 
of the March 2003 CLIAC meeting on direct access testing; a 
presentation on Lab Tests Online; a report on the first meeting of the 
Secretary's Advisory Committee on Genetics, Health and Society; and 
several presentations on CDC's various genetic testing activities.
    Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise indicated). 
Speakers must also submit their comments in writing for inclusion in 
the meetings Summary Report. Written Comments: For individuals or 
groups unable to attend the meeting, CLIAC accepts written comments 
until the date of the meeting (unless otherwise stated). However, the 
comments should be received at least one week prior to the meeting date 
so that the comments may be made available to the Committee for their 
consideration and public distribution. Written comments, one hard copy 
with original signature, should be provided to the contact person 
below. Written comments will be included in the meetings Summary 
Report.
    Contact Person for Additional Information: Rhonda Whalen, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory Systems, 
Public Health Practice Program Office, CDC, 4770 Buford Highway, NE., 
Mailstop F-11, Atlanta, Georgia 30341-3717; telephone (770) 488-8042; 
fax (770) 488-8279; or via e-mail at [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: August 20, 2003.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 03-22008 Filed 8-27-03; 8:45 am]
BILLING CODE 4163-18-P